Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1

SIMPLE SUMMARY: Inhibition of the androgen receptor (AR) remains the mainstay treatment for prostate cancer. All current therapies involving AR inhibition either directly or indirectly target its ligand-binding domain (LBD). We have developed the first novel compounds which target the N-terminal dom...

Descripción completa

Detalles Bibliográficos
Autores principales: Obst, Jon K., Mawji, Nasrin R., Teskey, Simon J. L., Wang, Jun, Sadar, Marianne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773799/
https://www.ncbi.nlm.nih.gov/pubmed/35053548
http://dx.doi.org/10.3390/cancers14020386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773799/
https://www.ncbi.nlm.nih.gov/pubmed/35053548
http://dx.doi.org/10.3390/cancers14020386

Ejemplares similares